Quick Answer
Regenerative Medical Technology Group Inc. reported Total Revenue of $4.11 million for fiscal year 2024.
Regenerative Medical Technology Group Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.11M +70.4% |
$2.41M +57.5% |
$1.53M +249.5% |
$437.9K +695.0% |
$55.1K +83.0% |
$30.1K -39.9% |
| Net Income | -$5.56M +43.3% |
-$9.81M -78.2% |
-$5.51M +57.3% |
-$12.88M -118.5% |
-$5.90M -135.0% |
-$2.51M -21.9% |
| Diluted EPS | -$0.44 +44.3% |
-$0.79 -75.6% |
-$0.45 +59.8% |
-$1.12 | — | — |
| Total Assets | $3.82M +32.7% |
$2.88M -64.4% |
$8.08M -13.2% |
$9.31M +4134.9% |
$219.7K +733.0% |
$26.4K -23.8% |
| Cash and Equivalents | — | $530.5K -67.8% |
$1.65M -44.8% |
$2.98M +6902.7% |
$42.5K +81.9% |
$23.4K -24.2% |
| Stockholders Equity | -$27.36M -25.5% |
-$21.80M -81.9% |
-$11.98M -77.3% |
-$6.76M -5.4% |
-$6.41M +12.9% |
-$7.36M -62.1% |
| Operating Income | $81.2K +111.4% |
-$715.2K | — | — | — | — |
| Gross Profit | $2.82M +68.5% |
$1.68M +91.1% |
$877.0K +484.1% |
$150.1K +1249.2% |
$11.1K +143.8% |
-$25.4K -39.5% |
| Shares Outstanding | 12.54M +0.4% |
12.49M +0.4% |
12.44M +3.0% |
12.09M +11.2% |
10.87M +36.6% |
7.96M +62.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.18M | +19.7% | +20.0% |
| Net Income | September 30, 2025 | -$4.35M | -390.8% | -233.4% |
| Diluted EPS | September 30, 2025 | -$0.35 | -400.0% | -250.0% |
| Total Assets | September 30, 2025 | $4.52M | +40.0% | +0.7% |
| Cash and Equivalents | September 30, 2025 | $1.19M | — | -26.5% |
| Stockholders Equity | September 30, 2025 | -$30.05M | -12.5% | -3.6% |
| Operating Income | September 30, 2025 | -$445.8K | -2368.7% | -78.2% |
| Gross Profit | September 30, 2025 | $501.6K | -32.9% | -14.4% |
| Shares Outstanding | September 30, 2025 | 12.54M | +0.0% | +0.0% |
- Regenerative Medical Technology Group Inc. reported Total Revenue of $4.11 million for fiscal year 2024.
- Regenerative Medical Technology Group Inc. showed an increase of +70.4% in Total Revenue compared to the prior fiscal year.
- Regenerative Medical Technology Group Inc. reported Net Income of -$5.56 million for fiscal year 2024.
- Regenerative Medical Technology Group Inc. showed an increase of +43.3% in Net Income compared to the prior fiscal year.
- Regenerative Medical Technology Group Inc. reported Diluted EPS of $0.44 per share (loss) for fiscal year 2024.
- Regenerative Medical Technology Group Inc. showed an increase of +44.3% in Diluted EPS compared to the prior fiscal year.
- Regenerative Medical Technology Group Inc. reported Total Assets of $3.82 million for fiscal year 2024.
- Regenerative Medical Technology Group Inc. showed an increase of +32.7% in Total Assets compared to the prior fiscal year.
- Regenerative Medical Technology Group Inc. reported Cash and Equivalents of $530.5 thousand for fiscal year 2023.
- Regenerative Medical Technology Group Inc. showed a decrease of -67.8% in Cash and Equivalents compared to the prior fiscal year.
- Regenerative Medical Technology Group Inc. reported Stockholders Equity of -$27.36 million for fiscal year 2024.
- Regenerative Medical Technology Group Inc. showed a decrease of -25.5% in Stockholders Equity compared to the prior fiscal year.
- Regenerative Medical Technology Group Inc. reported Operating Income of $81.2 thousand for fiscal year 2024.
- Regenerative Medical Technology Group Inc. showed an increase of +111.4% in Operating Income compared to the prior fiscal year.
- Regenerative Medical Technology Group Inc. reported Gross Profit of $2.82 million for fiscal year 2024.
- Regenerative Medical Technology Group Inc. showed an increase of +68.5% in Gross Profit compared to the prior fiscal year.
- Regenerative Medical Technology Group Inc. reported Shares Outstanding of 12.54 million shares for fiscal year 2024.
- Regenerative Medical Technology Group Inc. showed an increase of +0.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: